NCT06776770
Recruiting
Phase 1
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Previously Untreated Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center1 site in 1 country52 target enrollmentStarted: August 3, 2024Last updated:
InterventionsAdebrelimab
DrugsAdebrelimab
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- Enrollment
- 52
- Locations
- 1
- Primary Endpoint
- Dose-limiting toxicity（DLT）
Overview
Brief Summary
In this study, the combination of Adebrelimab (PD-L1 monoclonal antibody) on the basis of standard treatment (two-drug chemotherapy regimen of fluorouracil and platinum drugs) may enhance the immune response in order to enhance the killing effect on tumor cells and bring survival benefits to patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
Detailed Description
This study is divided into two phases: Phase Ib is a study on the tolerance and safety of Adebrelimab combined with capecitabine and oxaliplatin in the treatment of patients with advanced solid tumors; Phase II is a single-arm, open-label clinical study to observe and evaluate the improvement of objective response rate (ORR) in advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma treated with adebrelimab combination therapy. A total of 52 subjects are expected to be enrolled in this study.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The patients voluntarily participated in the study and signed the informed consent;
- •≥ 18 years old (calculated on the day of signing informed consent), both male and female;
- •Patients with pathologically confirmed gastric cancer (GC) or gastroesophageal junction cancer (GEJC) who were histologically confirmed to be adenocarcinoma and had not received antineoplastic therapy for GC or GEJC;
- •No prior systemic therapy for advanced or metastatic disease. Prior adjuvant or neoadjuvant chemotherapy for GC and GEJC,Radiotherapy or chemoradiotherapy, provided that the last dose of the last drug (based on the last dose) occurred at least 6 months prior to enrollment. Palliative radiotherapy is allowed, but it must be completed 2 weeks before enrollment;
- •Human epidermal growth factor receptor 2 negative or unknown;
- •At least one measurable lesion according to the solid tumor efficacy evaluation criteria (RECIST v1.1);
- •The Eastern Cooperative Oncology Group (ECOG) physical status score was 0-
- •Expected survival \> 12 weeks;
- •Adequate organ and bone marrow function, as defined below: A) Neutrophil count (ANC) ≥ 1,500/mm3 (1.5 × 10 \^ 9/L); B) Platelet count (PLT) ≥ 75,000/mm3 (75 × 10 \^ 9/L); C) hemoglobin (Hb) ≥ 8 G/dL (80 G/L); D) Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 40 ml/min; E) Total bilirubin (BIL) ≤ 1.5 times the upper limit of normal (ULN); F) Aspartate transaminase or Alanine transaminase ≤ 2.5 times the upper limit of normal (ULN), and ≤ 5 × ULN for patients with liver metastasis; G) International normalized ratio (INR) ≤ 1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 times ULN; H) Urine protein \< 2 +; if urine protein ≥ 2 +, 24-hour urine protein quantification shows that protein must be ≤ 1 G; I) Thyroid-stimulating hormone (TSH) ≤ upper limit of normal (ULN); if abnormal, T3 and T4 levels should be investigated, and normal T3 and T4 levels can be included.
- •10.Female subjects of childbearing age must have a negative serum pregnancy test within 3 days prior to the start of study medication and be willing to use a medically approved highly effective contraceptive method (e.g., intrauterine device, contraceptive pill, or condom) for the duration of the study and for 3 months after the last dose of study medication; Male subjects with a female partner of childbearing age were surgically sterilized or agreed to use an effective method of contraception for the duration of the study and for 3 months after the last study dose.
Exclusion Criteria
- •Previous treatment with PD-1/PD-L1 antibodies, cytotoxic T lymphocyte-associated antigen-4 antibodies, or other PD-1/PD-L1 inhibitors;
- •Past hypersensitivity to monoclonal antibodies and inactive ingredients of this product;
- •Previous use of immunosuppressive drugs within 14 days prior to the first dose of study drug, excluding nasal and inhaled corticosteroids or physiologic doses of systemic steroid hormones (i.e., up to 10 mg/day of prednisolone or pharmacophysiologically equivalent doses of other corticosteroids).；
- •Vaccination with live attenuated vaccine within 4 weeks before the first dose or planned during the study;
- •Patients with clinical signs and symptoms of central nervous system metastasis or other evidence that central nervous system metastasis has not been controlled are not suitable for inclusion according to the judgment of the investigator, and those with meningeal metastasis history or symptoms and signs need to be excluded;
- •Toxicity of previous antineoplastic therapy did not recover to the level of CTCAE v5.0 ≤ 1 or the level specified in the inclusion/exclusion criteria; except for other toxicities such as alopecia, which the investigator considered did not pose a safety risk to the patient;
- •Advanced patients with symptoms, dissemination to the viscera, and risk of life-threatening complications in the short term (including patients with uncontrollable massive exudates \[thoracic, pericardial, abdominal\], pulmonary lymphangitis, and liver involvement of more than 30%);
- •Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis,Hyperthyroidism, hypothyroidism; subjects with vitiligo or complete remission of asthma in childhood without any intervention in adulthood can be included; subjects with asthma requiring medical intervention of bronchodilators can not be included);
- •Any other malignancy diagnosed within 3 years prior to study entry, except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix;
- •Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV DNA ≥ 500 IU/ml), hepatitis C (hepatitis C antibody positive, and hepatitis C virus-RNA above the detection limit of the analytical method), or co-infection with hepatitis B and hepatitis C; 11.Myocardial infarction, severe/unstable angina, NYHA class 2 or greater cardiac dysfunction, and poorly controlled arrhythmias (including Corrected QT Interval interval \> 450 ms in men and \> 470 ms in women) within 6 months prior to study entry. QTcF interval was calculated by Fridericia formula), symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism); 12.Hypertension that is not well controlled by antihypertensive medication (systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg);
Arms & Interventions
Adebrelimab plus capecitabine and oxaliplatin
Experimental
Phase I: Cohort 1: Adebrelimab 10 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle; Cohort 2: Adebrelimab 1200 mg or 20 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle.
Phase II: Adebrelimab (RP2D, Q3W) + (XELOX regimen), with a 3-week (21-day) treatment cycle.
XELOX regimen：Oxaliplatin 130 mg/m2 iv.gtt d1，Capecitabine 1,000 mg/m2 p.o.b.i.d.d1~14
Intervention: Adebrelimab (Drug)
Outcomes
Primary Outcomes
Dose-limiting toxicity（DLT）
Time Frame: 48 months
Dose-limiting toxicity
Maximum tolerated dose (MTD)
Time Frame: 48 months
Maximum tolerated dose
Recommended Dose for Phase II Clinical Study (RP2D)
Time Frame: 48 months
Recommended Dose for Phase II Clinical Study
Objective Response Rate (ORR)
Time Frame: 48 months
Objective Response Rate
Secondary Outcomes
- Median progression-free survival (PFS)(48 months)
- Time-To-Progression (TTP)(48 months)
- Disease control rate (DCR)(48 months)
- Duration of Response (DoR)(48 months)
- overall survival (OS)(48 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaLocally Advanced or Metastatic Esophageal Squamous Cell CarcinomaNCT06339619Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University32
Active, not recruiting
Phase 2
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast CancerBreast CancerHR+/HER2- Breast CancerNCT06599216Harbin Medical University30
Recruiting
Phase 4
Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric AdenocarcinomaLocally Advanced Gastric AdenocarcinomaNCT06192186Yang Jianjun, PhD110
Withdrawn
Not Applicable
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)Esophageal Squamous Cell CarcinomaNCT06420908Hebei Medical University Fourth Hospital30
Recruiting
Phase 2
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal CancerMetastatic Colorectal CancerNCT06231017The First Affiliated Hospital of Zhengzhou University36